The latest clinical data from three key pipeline projects (namely senaparib (IMP4297), IMP1734 (also known as EIK1003), and IMP1707 (also known as EIK1004)) have been accepted for poster presentation at the 2026 European Society for Medical Oncology (ESMO) Congress.

The accepted data includes: (i) the latest progression-free survival (PFS) data from the Phase III FLAMES study of senaparib as first-line maintenance therapy for advanced ovarian cancer; (ii) the latest data from multiple cohorts of the ongoing Phase I/II study of IMP1734, covering monotherapy, combination therapy with paclitaxel for advanced solid tumors, and combination therapy with abiraterone for metastatic prostate cancer; and (iii) preliminary results from the first-in-human Phase I/II study of IMP1707, a central nervous system-penetrant selective PARP1 inhibitor, in patients with HRR-mutated advanced solid tumors.

The ESMO Congress is one of the most influential academic conferences in the global oncology field. This year's congress is scheduled to take place in Madrid, Spain, from October 23 to 27, 2026.